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For the clinical applications of regenerative medicine, 
induced pluripotent stem cells (iPSCs) (all acronyms 
are defined in the Glossary at the end of the text) 
have advantages over embryonic stem cells (ESCs) in 
histocompatibility and the lack of reliance on embryo 
derivation. Induction of pluripotency can be achieved 
by transiently expressing a minimal set of transcription 
factors (TFs) to reprogram differentiated cells. Direct 
reprogramming of somatic cells into progenitor stem 
or other mature cells would eliminate the need to make 
iPSCs, and then direct differentiation and select the desired 
lineage. Another advantage of direct reprogramming is that 
by avoiding the pluripotent step, one mitigates the risk of 
tumorigenicity. Direct reprogramming requires knowledge 
of the reprogramming factors and knowledge of the culture 
conditions necessary to maintain the induced multipotent 
stem cells. The culture conditions for mouse trophoblast 
stem cells (TSCs) were defined in the 1990s (1,2). 
Knowledge of how to reprogram mouse fibroblast cells to 
multipotent TSC has now been provided by two recent 
publications from the Buganim (3) and the Schorle labs (4). 
These studies inform not only regenerative medicine but 
will also aid our understanding of normal and pathological 
placental development in early pregnancy.
More than 12 TFs related to TSC maintenance or 
reprogramming in general were transiently expressed and 
tested for their ability to induce TSC from mouse fibroblasts 
(3,4). Table 1 lists the induction and proof of validity of 
the induced TSC (iTSC) in each report; comparing the 
reprogramming, maintenance, and differentiation of 
iTSC in vitro and in vivo, as well as the transcriptome and 
epigenetic modification of iTSC compared with blastocyst-
derived TSC (bdTSC). 
Of the TFs tested, three were identified in both 
reports as necessary for successful TSC induction, which 
were GATA Binding Protein 3 (Gata3), Eomesodermin 
(Eomes), and Transcription factor AP-2 gamma (Tfap2c). 
Surprisingly, genes like TEA domain transcription factor 
4 (Tead4), E74 like ETS transcription factor 5 (Elf5) and 
caudal type homeobox 2 (Cdx2), which are known to be 
essential in TSC initiation and maintenance were not 
among them (Figure 1). Eomes and Tfap2c bind to Tead4, 
Gata3 and Elf5 genes, and positively regulate the expression 
of Elf5 (5), which is gatekeeper gene in trophoblast lineage 
differentiation in early blastocyst (6). Triple occupancy of 
Elf5, Eomes and Tfap2c were enriched in genes related to 
TSC proliferation and potency, including themselves (7). 
Gata3 binds to and positively regulates the expression 
Cdx2 (8), which increases the expression of itself as well 
as Elf5 and Eomes (5). Gata3 also induces the expression 
of Eomes independent of Cdx2 (9). E26 avian leukemia 
oncogene 2 (Ets2) is downstream of Eomes and directly 
regulates the transcription of Cdx2 (10). Eomes, Tfap2c, 
Gata3 and Ets2 function coordinately to activate their 
own endogenous expression and the expression of other 
genes involved in TSC initiation and maintenance, thus 
forming a self-reinforcing auto-regulatory circuitry. Ets2 
was found to exist in 4 of the 5 genotyped iTSC clones by 
the Buganim lab (3), suggesting that Ets2 may promote 
successful reprogramming. The Schorle lab (4) identified 
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Table 1 Induction of TSC from mouse fibroblasts and its validation.
Parameters tested Buganim lab Schorle lab
Reprogramming, maintenance, and validation of iTSC 
Factors for reprogramming Gata3, Eomes, and Tfap2c ± Myc GETM >> GET Gata3, Eomes, Tfap2c, and Ets2 GETE 
FGF4 dependence + +
Serum-free defined medium + +
MesEpiTransform (MET) Epithelial markers Cdh1, Krt18, Dsp, and Ocln increased 
in small increments during 1–4 days, large 6–8 days. 
Mesenchymal markers Cdh2, Des, Fn1, and Cldn1 sharply 
decreased by 1 day. Key MET genes such as Twist1, 
Zeb2, Snai2, Foxc2, Gsc, Mmp3, and Snai1 substantial 
downregulation by 2 days
Not tested 
Epigenetic DNA methylation and 
histone acetylation
Hand1 and Elf5 hypomethylation in iTSC or bdTSC; 
Nanog promoter hypermethylation in iTSC. Low level of 
H4K37ac for Oct4 and Nanog, Thy1 and Postn. H2A.X 
normal deposition
Global DNA methylation similar between 
iTSCs and TSC-EGFP or TSC6.5. Promoter 
DMRs: Elf5, Tead4, Hand1 hypomethylation 
in iTSC. Oct4 hypermethylation in TSC
Pluripotent intermediate 
Necessary
No (GETM can’t induce iPSC in ESC culture condition; 
TSC culture condition does not support iPSC induction 
using OSKM). GETM induces iTSC in Oct4 null MEF
No (no Oct4 and Nanog was not detected 
during iTSC induction; GETE failed to 
induce TSC from ESC)
Transcriptome Similar between iTSC and bdTSC Similar between iTSC and TSC
Differentiation of iTSC in vitro and in vivo
% differentiated giant cells after 
FGF4 removal (flow cytometry)
2–4N from 49% to 35% by day 10, >4N from 27% to 51% 
by day 10
Increasing percentage of polyploidy cells 
during 6 days of FGF4 removal
In vivo differentiation Form subcutaneous hemorrhagic lesion. iTSC chimera 
contributes to placenta structure
Form subcutaneous hemorrhagic lesion, 
iTSC chimera contributes to placenta 
structure
In vitro differentiation Ctsq, Prl3b1, Prl3d1, Prl2c2 (TGC), Tpbpa (spongiotroph) 
and Cga (syncytiotroph) increased by 4–8 days of FGF4 
removal. Cdx2 and Eomes decreased ~50% and 80% by 
day 2
Ctsq, Prl3b1, Prl3d1, Prl2c2 increased. 
Cdx2 decreased 90% by day 3, 
comparable to TSC differentiation
Cdh1/2, cadherin 1/2; Cdx2, caudal type homeobox 2; Cga, chorionic gonadotropin subunit alpha; Cldn1, claudin 1; Ctsq, cathepsin Q; 
Des, desmin; DMR, differentially methylated region; Dsp, desmoplakin; Elf5, E74 like ETS transcription factor 5; Eomes, eomesodermin; 
ESC, embryonic stem cell; Ets2, E26 avian leukemia oncogene 2; FGF4, fibroblast growth factor 4; Fn1, fibronectin; Foxc2, forkhead box 
protein C2; Gsc2, homeobox protein goosecoid 2; Gata3, GATA binding protein 3; Hand1, heart and neural crest derivatives-expressed 
protein 1; H3K27ac, histone 3 lysine 27 acetylation; iPSC, induced pluripotent stem cell; Krt18, keratin, type I cytoskeletal 18; MEF, mouse 
embryonic fibroblast; MET, MesEpiTrans, mesenchymal to epithelial transformation; Mmp3, matrix metallopeptidase 3; Myc, Myc proto-
oncogene protein; Ocln, occludin; Oct4, octamer-binding transcription factor 4; OSKM, Oct4, Sox2, Klf4 and Myc; Postn, Periostin; 
Prl2c2, prolactin family 2, subfamily c, member 2; Prl3b1, prolactin family 3, subfamily b, member 1; Prl3d1, prolactin family 3, subfamily 
d, member 1; Snai1/2, zinc finger protein SNAI1/2; Tead4, TEA domain transcription factor 4; Tfap2c, transcription factor AP-2 gamma; 
TGFβ, transforming growth factor beta; Thy1, Thy-1 cell surface antigen; Tpbpa, trophoblast-specific protein alpha; TSC, trophoblast stem 
cell; Twist1, twist-related protein 1; Zeb2, zinc finger E-box binding homeobox 2.
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Ets2 as one of the four TFs necessary for TSC induction. 
Note that the Schorle lab (4) used a shorter induction time 
of 10 days instead of the 20 days used by the Buganim lab (3), 
which may explain the difference in the necessity of Ets2. 
As with bdTSC, iTSC in both studies can be maintained in 
vitro with mouse embryonic fibroblast conditioned medium 
supplemented with fibroblast growth factor 4 (FGF4) 
or chemically defined TX medium supplemented with 
transforming growth factor β (TGF-β) (11). 
TSC grow as epithelium and if epithelium formation is 
disturbed, potency is lost and differentiation occurs (12). 
Interestingly, although TFs that maintain mesenchymal 
state were lost in the first 2 days, it took 6–8 days to activate 
epithelial markers (Table 1). Follow-up studies should test 
for the kinetics of TSC-specific mRNA and epigenetic 
change during induction.
Reprogramming involves significant epigenetic 
changes, and it is important that the reprogrammed 
cell type resembles its naturally derived equivalent 
epigenetically. Fibroblast-derived iTSC have similar 
epigenetic profiles compared with bdTSC, as opposed 
to TSC differentiated in vitro from ESC, which is not 
complete largely due to epigenetic barriers (13). Both 
groups showed hypomethylation and activation of the 
TSC gatekeeper gene Elf5 and hypermethylation of ESC 
lineage markers octamer-binding transcription factor 4 
(Oct4) or Nanog. Global DNA methylation signatures of 
iTSC are comparable to bdTSC (4). Histone acetylation 
analysis further supports the successful induction of iTSC. 
Histone 3 lysine 27 acetylation (H3K27ac) marks accessible 
chromatin for transcription. TSC-specific gene regions 
were more enriched with H3K27ac in iTSC, while genes 
related to ESC such as Nanog and Oct4, or fibroblast 
such as Thy1 and periostin (Postn, aka osteoblast Specific 
Factor) showed lower H3K27ac levels (Table 1). In addition, 
genome-wide deposition pattern of histone variant H2A.
X in iTSC resembles that in bdTSC (3). Together, they 
showed that iTSC are comparable to iTSC epigenetically. 
Further evidence of the validity of iTSC includes its 
differentiation potential both in vitro and in vivo. During 
in vitro differentiation of iTSC, the loss of potency factor 
Cdx2 and Eomes and gain of differentiation factors such 
as trophoblast specific protein alpha (Tpbpa), prolactin 
family 3, subfamily d, member 1 (Prl3d1) (Table 1) 
resembled bdTSC both in chronological sequence and 
magnitude. However, although >50% TSC differentiated 
to >4N giant cells, over a third of 2–4N cells remained 10 
days after FGF4 removal. Whether the 2–4N cells were 
terminally differentiated or differentiating cells with limited 
proliferation potential remains unknown. Similar to the 
concern of tumorigenicity in iPSC-based therapy, it can be 
a potential problem if these cells continue to proliferate in 
differentiation milieu in vivo. Upon subcutaneous injection 
into nude mice, iTSC formed transient hemorrhagic lesions 
resembling invading trophoblast giant cells observed during 
implantation. iTSC also contributed to placental structures 
when injected into blastocyst. However, iTSC induced by 
the TF cocktail lacking Ets2 in Buganim lab’s report (3) 
seemed to have lower contribution to developing placenta. 
Both groups showed that iTSC induction was not 
associated with iPSC intermediate stage. The less successful 
efforts to differentiate ESC into TSC further supports direct 
TSC reprogramming. The supposed proliferative advantage 
of iPSCs over direct reprogramming is questionable, when 
the efficiency of subsequent differentiation and selection 
is taken into consideration. And there is proliferative 
potential in some directly reprogrammed multipotent stem 
cells, variable though that may be. Direct reprogramming 
faces similar efficacy and safety issues as the two-step iPSC 
induction and directed differentiation. But the encouraging 
results of iTSC induction from fibroblasts indicate there 
is no monopoly on ideas of how to best proceed with 
reprogramming and regenerative medicine.
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